Twitxy Saved

Martijn Arns

Verified account This account is verified. Learn more

@Brainclinics

Brainclinics Foundation | Applied Neuroscientist | TMS | Psychedelics | Ibogaine | Neurofeedback/BCI | Depression | Heart-Brain Coupling |
Nijmegen (NL) brainclinics.com/masterclass/ma… Joined May 2010
975 Following 3.7K Followers 5.5K Posts

Latest posts 5

Pinned post

Martijn Arns Verified account @Brainclinics
Registration is open for the 2027 Brainclinics Foundation Masterclass: Psychedelics & TMS (March 17-19, Nijmegen, NL).

Interventional psychiatry is moving fast. Single-day TMS protocols, the first results for transcranial focused ultrasound (tFUS), and FDA decisions on psilocybin, LSD and MDMA expected in 2027. This time the Brainclinics Foundation Masterclass brings brain stimulation and psychedelics together with a great line-up of speakers: @RCarhartHarris, @RachelYehuda, @NoahSPhilipMD, Helena Aicher, Iris Dalhuisen and @JonathanDownar

Max 50 participants, 90-minute keynotes, hands-on and ask-the-expert sessions, and a copy of Robin’s new book 'How Psychedelics Work' for every participant. Previous editions all sold out.

Sign-up here: brainclinics.com/masterclass/ma…
Martijn Arns Verified account @Brainclinics
Three different psychedelics, three different indications, one disorder...
How to read psychedelic trial outcomes in depression

Psychedelics produce an unmistakable experience, so most patients know what they got. True double-blinding is impossible, and that undermines Δ-MADRS and effect sizes, because both depend on the placebo arm. A more robust read: compare active-arm remission with large open-label effectiveness data. Both then include specific + non-specific effects, a fair proxy for what you’d see in clinical practice.

Second, indication matters. MDD, adjunctive and TRD carry very different expected remission rates. STAR*D (~4,000 pts, sequential treatment steps) shows remission falling 37% → 31% → 14% → 13% with each failed treatment (inset).

Read in that context:
• $CMPS COMP360: 18% blinded looks low, but beats STAR*D step 3 (14%) in TRD; 30% open-label is on par with TMS (29.5%)
• $DFTX DT120: 24% in MDD sits below STAR*D steps 1–2, though higher 46% remisison with redosing/follow-up (interim data)
• $HELP HLP003: highest remission (51%) and highest placebo (18%), likely reflecting add-on to ongoing AD + EMBARK psychological support

Cross-trial; definitions differ.
6 replies 6 reposts 36 likes 2.8K views View on X
Martijn Arns Verified account @Brainclinics
Exciting results for HLP003 $HELP Phase-3 trial, 39% remission at day 2, improving to 51% at 6 weeks. The trajectories show quite significant effect of the 2nd dose in line with earlier $CMPS studies. Delta MADRS at 7.6 points is better than expected despite quite some placebo response and better than CMPS and other adjunctive treatments, albeit this not being TRD patients and adjunctive treatment. Three SAE's in the HLP003 group, one suicide attempt which occured 50 dys after treatment, likely unrelated to the treatment. Two other SAE's were listed as 'depression'.
1 replies 4 reposts 31 likes 5.6K views View on X
Martijn Arns Verified account @Brainclinics
The FDA’s first decisions on psilocybin, LSD and MDMA are expected in 2027. Where will you be when psychedelics enter clinical practice?

Our answer: Nijmegen (NL), March 17–19, at the TMS & Psychedelic Masterclass. One day on TMS certification, one on psychedelics, one on the latest in brain stimulation, with @RCarhartHarris, Rachel Yehuda, @NoahSPhilipMD, @JonathanDownar, Helena Aicher and Iris Dalhuisen.

Included with your registration: Robin’s 'How Psychedelics Work' book, published weeks before the course, and an option to have it signed by the author!

Registration open: brainclinics.com/masterclass/ma…